| Outcome |
Relative effect 95%CI |
LoD |
Trt. better when |
|
I2 |
k (RCT/OBS)
|
Bayesian probability
|
Overall ROB
|
Publication bias |
Degree of certainty |
Endpoint importance |
Published MA |
efficacy endpoints 00 |
| deaths (OS) | 0.75 [0.61, 0.92] | | < 1 | | 54% | 3 studies (3/-) | 99.7 % | some concern | not evaluable | moderate | crucial | - |
| progression or deaths (PFS) | 0.74 [0.56, 0.97] | | < 1 | | 80% | 3 studies (3/-) | 98.4 % | some concern | not evaluable | moderate | important | - |
| DCR | 1.44 [0.95, 2.19] | | > 1 | | 0% | 1 study (1/-) | 95.8 % | NA | not evaluable | | non important | - |
| objective responses (ORR) | 2.82 [2.02, 3.93] | | > 1 | | 0% | 3 studies (3/-) | 100.0 % | some concern | not evaluable | moderate | non important | - |
safety endpoints 00 |
| AE (any grade) | 1.69 [0.44, 6.51] | | < 1 | | 57% | 2 studies (2/-) | 22.4 % | low | not evaluable | high | non important | - |
| AE (grade 3-4) | 1.15 [0.87, 1.52] | | < 1 | | 0% | 2 studies (2/-) | 17.1 % | some concern | not evaluable | moderate | non important | - |
| AE leading to death (grade 5) | 0.80 [0.40, 1.61] | | < 1 | | 0% | 2 studies (2/-) | 73.6 % | some concern | not evaluable | moderate | non important | - |
| AE leading to treatment discontinuation (any grade) | 1.81 [1.16, 2.83] | | < 1 | | 0% | 2 studies (2/-) | 0.4 % | some concern | not evaluable | moderate | non important | - |
| AE leading to treatment discontinuation (grade 3-4) | 3.04 [1.32, 6.97] | | < 1 | | 0% | 1 study (1/-) | 0.4 % | NA | not evaluable | | non important | - |
| SAE (any grade) | 1.38 [0.92, 2.07] | | < 1 | | 0% | 1 study (1/-) | 6.1 % | NA | not evaluable | | non important | - |
| STRAE (grade 3-4) | 0.30 [0.22, 0.41] | | < 1 | | 0% | 1 study (1/-) | 100.0 % | NA | not evaluable | | non important | - |
| TRAE (any grade) | 1.66 [1.09, 2.51] | | < 1 | | 0% | 1 study (1/-) | 0.9 % | NA | not evaluable | | non important | - |
| TRAE (grade 3-4) | 2.77 [1.36, 5.65] | | < 1 | | 0% | 1 study (1/-) | 0.3 % | NA | not evaluable | | non important | - |
| TRAE leading to death (grade 5) | 0.96 [0.03, 28.81] | | < 1 | | 0% | 1 study (1/-) | 50.9 % | NA | not evaluable | | non important | - |
| TRAE leading to discontinuation (any grade) | 0.53 [0.28, 1.00] | | < 1 | | 0% | 1 study (1/-) | 97.5 % | NA | not evaluable | | non important | - |
TRAE (grade 3-4) endpoints 00 |
| Abdominal pain TRAE (grade 3-4) | 0.48 [0.01, 24.29] | | < 1 | | 0% | 1 study (1/-) | 64.1 % | NA | not evaluable | | non important | - |
| Adrenal insufficiency TRAE (grade 3-4) | 0.48 [0.01, 24.29] | | < 1 | | 0% | 1 study (1/-) | 64.1 % | NA | not evaluable | | non important | - |
| Alopecia TRAE (grade 3-4) | 0.48 [0.01, 24.29] | | < 1 | | 0% | 1 study (1/-) | 64.1 % | NA | not evaluable | | non important | - |
| Anaemia TRAE (grade 3-4) | 0.24 [0.02, 2.64] | | < 1 | | 0% | 1 study (1/-) | 87.7 % | NA | not evaluable | | non important | - |
| Arthralgia TRAE (grade 3-4) | 0.48 [0.01, 24.29] | | < 1 | | 0% | 1 study (1/-) | 64.1 % | NA | not evaluable | | non important | - |
| Asthenia TRAE (grade 3-4) | 0.48 [0.01, 24.29] | | < 1 | | 0% | 1 study (1/-) | 64.1 % | NA | not evaluable | | non important | - |
| Colitis TRAE (grade 3-4) | 1.93 [0.09, 43.05] | | < 1 | | 0% | 1 study (1/-) | 34.1 % | NA | not evaluable | | non important | - |
| Constipation TRAE (grade 3-4) | 0.48 [0.01, 24.29] | | < 1 | | 0% | 1 study (1/-) | 64.1 % | NA | not evaluable | | non important | - |
| Cough TRAE (grade 3-4) | 0.48 [0.01, 24.29] | | < 1 | | 0% | 1 study (1/-) | 64.1 % | NA | not evaluable | | non important | - |
| Decreased appetite TRAE (grade 3-4) | 2.90 [0.14, 58.35] | | < 1 | | 0% | 1 study (1/-) | 24.6 % | NA | not evaluable | | non important | - |
| Diabetes TRAE (grade 3-4) | 0.48 [0.03, 7.71] | | < 1 | | 0% | 1 study (1/-) | 69.7 % | NA | not evaluable | | non important | - |
| Diarrhoea TRAE (grade 3-4) | 0.96 [0.09, 10.69] | | < 1 | | 0% | 1 study (1/-) | 51.3 % | NA | not evaluable | | non important | - |
| Dry skin TRAE (grade 3-4) | 0.48 [0.01, 24.29] | | < 1 | | 0% | 1 study (1/-) | 64.1 % | NA | not evaluable | | non important | - |
| Dysgeusia TRAE (grade 3-4) | 0.48 [0.01, 24.29] | | < 1 | | 0% | 1 study (1/-) | 64.1 % | NA | not evaluable | | non important | - |
| Dyspepsia TRAE (grade 3-4) | 0.48 [0.01, 24.29] | | < 1 | | 0% | 1 study (1/-) | 64.1 % | NA | not evaluable | | non important | - |
| Dyspnoea TRAE (grade 3-4) | 0.48 [0.01, 24.29] | | < 1 | | 0% | 1 study (1/-) | 64.1 % | NA | not evaluable | | non important | - |
| Eczema TRAE (grade 3-4) | 0.48 [0.01, 24.29] | | < 1 | | 0% | 1 study (1/-) | 64.1 % | NA | not evaluable | | non important | - |
| Fatigue TRAE (grade 3-4) | 1.45 [0.15, 14.03] | | < 1 | | 0% | 1 study (1/-) | 37.6 % | NA | not evaluable | | non important | - |
| Headache TRAE (grade 3-4) | 0.48 [0.01, 24.29] | | < 1 | | 0% | 1 study (1/-) | 64.1 % | NA | not evaluable | | non important | - |
| Hepatitis TRAE (grade 3-4) | 3.88 [0.20, 74.00] | | < 1 | | 0% | 1 study (1/-) | 18.6 % | NA | not evaluable | | non important | - |
| Hyperthyroidism TRAE (grade 3-4) | 0.48 [0.01, 24.29] | | < 1 | | 0% | 1 study (1/-) | 64.1 % | NA | not evaluable | | non important | - |
| Hypophysitis TRAE (grade 3-4) | 0.96 [0.03, 28.81] | | < 1 | | 0% | 1 study (1/-) | 50.9 % | NA | not evaluable | | non important | - |
| Hypothyroidism TRAE (grade 3-4) | 0.96 [0.03, 28.81] | | < 1 | | 0% | 1 study (1/-) | 50.9 % | NA | not evaluable | | non important | - |
| Increase AST TRAE (grade 3-4) | 3.75 [0.85, 16.64] | | < 1 | | 0% | 1 study (1/-) | 4.2 % | NA | not evaluable | | non important | - |
| Increased ALT TRAE (grade 3-4) | 2.45 [0.53, 11.36] | | < 1 | | 0% | 1 study (1/-) | 12.6 % | NA | not evaluable | | non important | - |
| Infusion-related reactions TRAE (grade 3-4) | 0.48 [0.01, 24.29] | | < 1 | | 0% | 1 study (1/-) | 64.1 % | NA | not evaluable | | non important | - |
| Leucopenia TRAE (grade 3-4) | 0.24 [0.01, 7.16] | | < 1 | | 0% | 1 study (1/-) | 79.2 % | NA | not evaluable | | non important | - |
| Maculopapular rash TRAE (grade 3-4) | 0.48 [0.01, 24.29] | | < 1 | | 0% | 1 study (1/-) | 64.1 % | NA | not evaluable | | non important | - |
| Myalgia TRAE (grade 3-4) | 0.48 [0.01, 24.29] | | < 1 | | 0% | 1 study (1/-) | 64.1 % | NA | not evaluable | | non important | - |
| Myositis TRAE (grade 3-4) | 0.96 [0.03, 28.81] | | < 1 | | 0% | 1 study (1/-) | 50.9 % | NA | not evaluable | | non important | - |
| Nausea TRAE (grade 3-4) | 0.48 [0.01, 24.29] | | < 1 | | 0% | 1 study (1/-) | 64.1 % | NA | not evaluable | | non important | - |
| Palmar-plantar erythrodysaesthesia syndrome TRAE (grade 3-4) | 0.96 [0.03, 28.81] | | < 1 | | 0% | 1 study (1/-) | 50.9 % | NA | not evaluable | | non important | - |
| Peripheral oedema TRAE (grade 3-4) | 0.48 [0.01, 24.29] | | < 1 | | 0% | 1 study (1/-) | 64.1 % | NA | not evaluable | | non important | - |
| Pneumonitis TRAE (grade 3-4) | 1.93 [0.09, 43.05] | | < 1 | | 0% | 1 study (1/-) | 34.1 % | NA | not evaluable | | non important | - |
| Pruritus TRAE (grade 3-4) | 0.96 [0.03, 28.81] | | < 1 | | 0% | 1 study (1/-) | 50.9 % | NA | not evaluable | | non important | - |
| Pyrexia TRAE (grade 3-4) | 0.48 [0.01, 24.29] | | < 1 | | 0% | 1 study (1/-) | 64.1 % | NA | not evaluable | | non important | - |
| Rash TRAE (grade 3-4) | 0.96 [0.03, 28.81] | | < 1 | | 0% | 1 study (1/-) | 50.9 % | NA | not evaluable | | non important | - |
| Severe skin reaction TRAE (grade 3-4) | 5.87 [0.33, 105.85] | | < 1 | | 0% | 1 study (1/-) | 11.8 % | NA | not evaluable | | non important | - |
| Stomatitis TRAE (grade 3-4) | 0.48 [0.01, 24.29] | | < 1 | | 0% | 1 study (1/-) | 64.1 % | NA | not evaluable | | non important | - |
| Thrombocytopenia TRAE (grade 3-4) | 0.48 [0.01, 24.29] | | < 1 | | 0% | 1 study (1/-) | 64.1 % | NA | not evaluable | | non important | - |
| Thyroiditis TRAE (grade 3-4) | 0.48 [0.01, 24.29] | | < 1 | | 0% | 1 study (1/-) | 64.1 % | NA | not evaluable | | non important | - |
| Vomiting TRAE (grade 3-4) | 0.48 [0.01, 24.29] | | < 1 | | 0% | 1 study (1/-) | 64.1 % | NA | not evaluable | | non important | - |
| Weight decreased TRAE (grade 3-4) | 0.96 [0.03, 28.81] | | < 1 | | 0% | 1 study (1/-) | 50.9 % | NA | not evaluable | | non important | - |
AE (grade 3-4) endpoints 00 |
| Abdominal pain AE (grade 3-4) | 0.89 [0.13, 6.01] | | < 1 | | 38% | 2 studies (2/-) | 54.7 % | some concern | not evaluable | moderate | non important | - |
| Acute kidney injury AE (grade 3-4) | 0.16 [0.02, 1.51] | | < 1 | | 0% | 1 study (1/-) | 94.5 % | NA | not evaluable | | non important | - |
| Alopecia AE (grade 3-4) | 0.47 [0.01, 23.97] | | < 1 | | 0% | 1 study (1/-) | 64.3 % | NA | not evaluable | | non important | - |
| Anaemia AE (grade 3-4) | 0.61 [0.25, 1.49] | | < 1 | | 37% | 2 studies (2/-) | 86.2 % | low | not evaluable | high | non important | - |
| Arthralgia AE (grade 3-4) | 0.48 [0.03, 7.71] | | < 1 | | 0% | 1 study (1/-) | 69.7 % | NA | not evaluable | | non important | - |
| Asthenia AE (grade 3-4) | 0.16 [0.02, 1.11] | | < 1 | | 0% | 2 studies (2/-) | 96.8 % | some concern | not evaluable | moderate | non important | - |
| Back pain AE (grade 3-4) | 3.88 [0.20, 74.00] | | < 1 | | 0% | 1 study (1/-) | 18.6 % | NA | not evaluable | | non important | - |
| Constipation AE (grade 3-4) | 0.71 [0.05, 9.27] | | < 1 | | 0% | 2 studies (2/-) | 60.3 % | low | not evaluable | high | non important | - |
| Cough AE (grade 3-4) | 0.32 [0.02, 4.18] | | < 1 | | 0% | 2 studies (2/-) | 80.6 % | some concern | not evaluable | moderate | non important | - |
| Decreased appetite AE (grade 3-4) | 0.62 [0.08, 4.71] | | < 1 | | 45% | 2 studies (2/-) | 67.9 % | some concern | not evaluable | moderate | non important | - |
| Diarrhoea AE (grade 3-4) | 0.42 [0.18, 1.02] | | < 1 | | 0% | 2 studies (2/-) | 97.3 % | some concern | not evaluable | moderate | non important | - |
| Dyspepsia AE (grade 3-4) | 0.12 [0.01, 2.61] | | < 1 | | 0% | 1 study (1/-) | 90.9 % | NA | not evaluable | | non important | - |
| Dyspnoea AE (grade 3-4) | 0.46 [0.12, 1.77] | | < 1 | | 0% | 2 studies (2/-) | 87.1 % | some concern | not evaluable | moderate | non important | - |
| Epistaxis AE (grade 3-4) | 0.24 [0.01, 7.07] | | < 1 | | 0% | 1 study (1/-) | 79.4 % | NA | not evaluable | | non important | - |
| Fatigue AE (grade 3-4) | 0.99 [0.39, 2.49] | | < 1 | | 0% | 2 studies (2/-) | 50.7 % | some concern | not evaluable | moderate | non important | - |
| Hypertension AE (grade 3-4) | 1.29 [0.73, 2.28] | | < 1 | | 0% | 1 study (1/-) | 18.8 % | NA | not evaluable | | non important | - |
| Increase AST AE (grade 3-4) | 1.66 [0.96, 2.86] | | < 1 | | 0% | 2 studies (2/-) | 3.6 % | low | not evaluable | high | non important | - |
| Increased ALT AE (grade 3-4) | 2.36 [0.97, 5.77] | | < 1 | | 0% | 2 studies (2/-) | 3.0 % | low | not evaluable | high | non important | - |
| Infusion-related reaction AE (grade 3-4) | 7.75 [0.44, 135.83] | | < 1 | | 0% | 1 study (1/-) | 8.3 % | NA | not evaluable | | non important | - |
| Nausea AE (grade 3-4) | 0.71 [0.11, 4.37] | | < 1 | | 0% | 2 studies (2/-) | 64.4 % | low | not evaluable | high | non important | - |
| Palmar–plantar erythrodysesthesia syndrome AE (grade 3-4) | 0.02 [0.00, 0.28] | | < 1 | | 0% | 1 study (1/-) | 99.7 % | NA | not evaluable | | non important | - |
| Peripheral oedema AE (grade 3-4) | 0.48 [0.01, 24.29] | | < 1 | | 0% | 1 study (1/-) | 64.1 % | NA | not evaluable | | non important | - |
| Proteinuria AE (grade 3-4) | 4.86 [0.62, 38.30] | | < 1 | | 0% | 1 study (1/-) | 6.8 % | NA | not evaluable | | non important | - |
| Pruritus AE (grade 3-4) | 0.71 [0.05, 9.27] | | < 1 | | 0% | 2 studies (2/-) | 60.3 % | low | not evaluable | high | non important | - |
| Pyrexia AE (grade 3-4) | 1.12 [0.25, 4.99] | | < 1 | | 0% | 2 studies (2/-) | 44.2 % | some concern | not evaluable | moderate | non important | - |
| Rash AE (grade 3-4) | 0.32 [0.01, 10.00] | | < 1 | | 61% | 2 studies (2/-) | 73.8 % | some concern | not evaluable | moderate | non important | - |
| Thrombocytopenia AE (grade 3-4) | 0.95 [0.23, 3.84] | | < 1 | | 0% | 1 study (1/-) | 53.0 % | NA | not evaluable | | non important | - |
| Vomiting AE (grade 3-4) | 0.95 [0.09, 10.54] | | < 1 | | 0% | 1 study (1/-) | 51.7 % | NA | not evaluable | | non important | - |
| Weight decreased AE (grade 3-4) | 0.24 [0.01, 7.07] | | < 1 | | 0% | 1 study (1/-) | 79.4 % | NA | not evaluable | | non important | - |
